Share this Page:
Results from the TRAXAR clinical trial to assess TRC105 plus axitinib in pre-treated patients with advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend.
Endoglin is an endothelial cell surface receptor that has a role in the development and growth of blood vessels (angiogenesis) in tumours. TRC105 is a monoclonal antibody to endoglin, which has been shown to have promising clinical activity in the treatment of metastatic RCC in a phase Ib clinical trial.
However, results from this randomised phase II study of axitinib with or without the endoglin antibody TRC105 in a total of 150 patients did not show an improvement in progression-free survival in patients with metastatic RCC after prior treatment with VEGF-targeted therapy.